The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B*5701 as a model of safety

Neuropsychopharmacology

Volumn 34, Issue 1, 2009, Pages 6-17

  Roses, Allen D ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Alzheimer's; Efficacy; Genome wide association; Pharmacogenetics; Pharmacovigilance; Safety

Indexed keywords

ABACAVIR; DNA MARKER; HLA B 5701 ANTIGEN; HLA B ANTIGEN; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; GENETIC ASSOCIATION; HUMAN; NONHUMAN; PHARMACOGENETICS; PREDICTOR VARIABLE; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DIDEOXYNUCLEOSIDES; DRUG DISCOVERY; DRUG HYPERSENSITIVITY; DRUG TOXICITY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HLA-B ANTIGENS; HUMANS; MODELS, BIOLOGICAL; PHARMACOGENETICS; SAMPLE SIZE; THIAZOLIDINEDIONES;

EID: 57649131090     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.153     Document Type: Review

References (98)

1. Adult and adolescent guidelines HIV [abacavir] (2008). http://www.Aidsinfo.Nih.Gov/contentfiles/adultandadolescentgl.Pdf.
2. Ahmadi KR, Weale ME, Xue ZY, Soranzo N, Yarnall DP, Briley JD et al (2005). A single-nucleotide polymorphism tagging set for human drug metabolism and transport. (see comment). Nat Genet 37: 84-89.
3. Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG (2003). Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 161: 41-54.
4. Anonymous (1992). New drug, antibiotic, and biological drug product regulations; accelerated approval - fda. Final rule. Fed Regist 57: 58942-58960.
5. Ashkenazi A, Herbst RS (2008). To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 118: 1979-1990.
6. Bahmanyar S, Higgins GA, Goldgaber D, Lewis DA, Morrison JH, Wilson MC et al (1987). Localization of amyloid beta protein messenger rna in brains from patients with Alzheimer's disease. Science 237: 77-80.
7. Brodbeck J, Balestra ME, Saunders AM, Roses AD, Mahley RW, Huang Y et al (2008). Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein e4 in primary cortical neurons. Proc Natl Acad Sci USA 105: 1343-1346.
8. Chang S, ran Ma T, Miranda RD, Balestra ME, Mahley RW, Huang Y et al (2005). Lipid- and receptor-binding regions of apolipoprotein e4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci USA 102: 18694-18699.
9. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G et al (1997). Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. [see comment]. Nat Med 3: 67-72.
10. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH et al (2007). A high-density whole-genome association study reveals that apoe is the major susceptibility gene for sporadic late-onset Alzheimer's disease. [see comment]. J Clin Psychiatry 68: 613-618.
11. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW et al (1993). Gene dose of apolipoprotein e type 4 allele and the risk of Alzheimer's disease in late onset families. [see comment]. Science 261: 921-923.
12. Dahlman I, Eaves IA, Kosoy R, Morrison VA, Heward J, Gough SC et al (2002). Parameters for reliable results in genetic association studies in common disease. Nat Genet 30: 149-150.
13. DREAM Trial Investigators Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N et al (2006). Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. [see comment] [erratum appears in lancet. 2006 nov 18;368(9549):1770]. Lancet 368: 1096-1105.
14. Dreses-Werringloer U, Lambert JC, Vingtdeux V, Zhao H, Vais H, Siebert A et al (2008). A polymorphism in calhm1 influences ca2+ homeostasis, abeta levels, and Alzheimer's disease risk. Cell 133: 1149-1161.
15. Dunys J, Kawarai T, Giaime E, Wilk S, Herrant M, Auberger P et al (2007). Study on the putative contribution of caspases and the proteasome to the degradation of aph-1a and pen-2. Neurodegener Dis 4: 156-163.
16. E15 definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories (2008). Http://www.Fda.Gov/cber/gdlns/iche15term.Htm.
17. Epstein RA (2007). Conflicts of interest in health care: who guards the guardians? Perspect Biol Med 50: 72-88.
18. Fovenyi J (2006). [Experiences of the dream trial]. Orvosi Hetilap 147: 2523-2526.
19. Frayling TM (2007). Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet 8: 657-662.
20. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J, The DTI (2004). Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the dream trial. Diabetologia 47: 1519-1527.
21. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L et al (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. [see comment]. Nature 349: 704-706.
22. Goldberg RB (2007). The new clinical trials with thiazolidinediones - dream, adopt, and Chicago: promises fulfilled? Curr Opin Lipidol 18: 435-442.
23. Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek DC (1987). Characterization and chromosomal localization of a cdna encoding brain amyloid of Alzheimer's disease. Science 235: 877-880.
24. Goldstein DB, Tate SK, Sisodiya SM (2003). Pharmacogenetics goes genomic. [erratum appears in nat rev genet. 2004 jan;5(1):76]. Nat Rev Genet 4: 937-947.
25. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J et al (2006). Variant of transcription factor 7-like 2 (tcf7l2) gene confers risk of type 2 diabetes. Nat Genet 38: 320-323.
26. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T et al (2003). Carboxyl-terminal-truncated apolipoprotein e4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci USA 100: 10966-10971.
27. Helgason A, Palsson S, Thorleifsson G, Grant SF, Emilsson V, Gunnarsdottir S et al (2007). Refining the impact of tcf7l2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 39: 218-225.
28. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W et al (2002). Genetic variations in hla-b region and hypersensitivity reactions to Abacavir. Lancet 359: 1121-1122.
29. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B et al (2001). Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 23: 1603-1614.
30. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K (2002). A comprehensive review of genetic association studies. Genet Med 4: 45-61.
31. Hisatomi T, Nakazawa T, Noda K, Almulki L, Miyahara S, Nakao S et al (2008). Hiv protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice. J Clin Invest 118: 2025-2038.
32. Hughes AR, Spreen WR, Mosteller M, Warren LL, Lai EH, Brothers CH et al (2008). Pharmacogenetics of hypersensitivity to abacavir: Pgx hypothesis to confirmation to clinical utility? Pharmacogenomics J, advance online publication, March 11, 2008; doi:10.1038/tpj.2008.3.
33. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE et al (2007). A genome-wide association study identifies alleles in fgfr2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39: 870-874.
34. Ioannidis JP (2007). Non-replication and inconsistency in the genome-wide association setting. Hum Hered 64: 203-213.
35. Jani-Acsadi A, Krajewski K, Shy ME (2008). Charcot-marie-tooth neuropathies: diagnosis and management. Semin Neurol 28: 185-194.
36. Kamino K, Sato S, Sakaki Y, Yoshiiwa A, Nishiwaki Y, Takeda M et al (1996). Three different mutations of presenilin 1 gene in early-onset Alzheimer's disease families. Neurosci Lett 208: 195-198.
37. Koeppen AH (2005). The pathogenesis of spinocerebellar ataxia. Cerebellum 4: 62-73.
38. Lago RM, Singh PP, Nesto RW (2007). Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. [see comment]. Lancet 370: 1129-1136.
39. Lai E, Riley J, Purvis I, Roses A (1998). A 4-mb high-density single nucleotide polymorphism-based map around human apoe. Genomics 54: 31-38.
40. Lee JH, Cheng R, Schupf N, Manly J, Lantigua R, Stern Y et al (2007). The association between genetic variants in sorl1 and Alzheimer disease in an urban, multiethnic, community-based cohort. Arch Neurol 64: 501-506.
41. Lesko LJ (2007). Paving the critical path: how can clinical pharmacology help achieve the vision? Clin Pharmacol Ther 81: 170-177.
42. Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L et al (2008). Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 65: 45-53.
43. Libioulle C, Louis E, Hansoul S, Sandor C, Farnir F, Franchimont D et al (2007). Novel Crohn's disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of ptger4. PLoS Genet 3: e58.
44. Mahley RW, Weisgraber KH, Huang Y (2006). Apolipoprotein e4: a causative factor and therapeutic target in neuropathology, including alzheimer's disease. [see comment]. Proc Natl Acad Sci USA 103: 5644-5651.
45. Malhotra AK, Murphy Jr GM, Kennedy JL (2004). Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161: 780-796.
46. Mallal S (2007). Predict-1: A novel randomised prospective study to determine the clinical utility of HLA-B*5701 screening to reduce abacavir hypersensitivity in hiv-1 infected subjects (study cna106030): 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention: Late Breaker Track B. Sydney, Australia.
47. Mallal S (2008). The predict-1 study: a randomized, double-blind trial to determine the clinical utility of HLA-B*5701 pharmacogenetic screening for abacavir hypersensitivity in hiv-infected patients (study cna106030). New Eng J Med 358: 568-579.
48. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C et al (2002). Association between presence of HLA-B*5701, hla-dr7, and hla-dq3 and hypersensitivity to hiv-1 reverse-transcriptase inhibitor abacavir. [see comment]. Lancet 359: 727-732.
49. Maron BJ, Hauser RG (2007). Perspectives on the failure of pharmaceutical and medical device industries to fully protect public health interests. Am J Cardiol 100: 147-151.
50. Martin ER, Lai EH, Gilbert JR, Rogala AR, Afshari AJ, Riley J et al (2000). Snping away at complex diseases: analysis of single-nucleotide polymorphisms around apoe in Alzheimer disease. Am J Hum Genet 67: 383-394.
51. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP et al (2008). Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 9: 356-369.
52. McKusick VA (2006). A 60-year tale of spots, maps, and genes. Annu Rev Genomics Hum Genet 7: 1-27.
53. McKusick VA (2007). Mendelian inheritance in man and its online version, omim. Am J Hum Genet 80: 588-604.
54. Meng Y, Lee JH, Cheng R, St George-Hyslop P, Mayeux R, Farrer LA et al (2007). Association between sorl1 and Alzheimer's disease in a genome-wide study. Neuroreport 18: 1761-1764.
55. Need AC, Motulsky AG, Goldstein DB (2005). Priorities and standards in pharmacogenetic research. Nat Genet 37: 671-681.
56. Nissen SE, Wolski K (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. [see comment] [erratum appears in n engl j med. 2007 jul 5;357(1):100.]. New Engl J Med 356: 2457-2471.
57. North BV, Curtis D, Martin ER, Lai EH, Roses AD, Sham PC et al (2004). Further investigation of linkage disequilibrium snps and their ability to identify associated susceptibility loci. Ann Hum Genet 68: 240-248.
58. Okura Y, Matsumoto Y (2008). DNA vaccine therapy for Alzheimer's disease: present status and future direction. Rejuvenation Res 11: 301-308.
59. Orr MS, Goodsaid F, Amur S, Rudman A, Frueh FW (2007). The experience with voluntary genomic data submissions at the fda and a vision for the future of the voluntary data submission program. Clin Pharmacol Ther 81: 294-297.
60. Passamonti L, Muglia M, Magariello A, Bellesi M, Conforti FL, Mazzei R et al (2004). Further evidence of genetic heterogeneity in autosomal dominant distal motor neuronopathy. Neuromuscul Disord 14: 705-710.
61. Peck C (2007). Preventing postmarketing changes in recommended doses and marketing withdrawals. Ernst Schering Res Found Workshop 59: 209-216.
62. Phillips EJ, Mallal SA (2008). Pharmacogenetics and the potential for the individualization of antiretroviral therapy. Curr Opin Infect Dis 21: 16-24.
63. Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS et al (2008). Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into an1792-associated meningoencephalitis. Neurodegener Dis 5: 194-196.
64. Raelson JV, Little RD, Ruether A, Fournier H, Paquin B, Van Eerdewegh P et al (2007). Genome-wide association study for Crohn's disease in the Quebec founder population identifies multiple validated disease loci. Proc Natl Acad Sci USA 104: 14747-14752.
65. Reichert JM (2003). Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov 2: 695-702.
66. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, et al, Rosiglitazone in Alzheimer's Disease Study G (2006). Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease*[see comment]. Pharmacogenomics J 6: 246-254.
67. Roses A (2008a). The medical and pharmaco-economic roles of pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B*5701 as a model of safety. Neuropsychopharmacol Rev. CNS Drug Discovery & Development: Challenges and Opportunities (in press).
68. Roses A (2008b). Stimulation of cholecystokinin-a receptors with gl181771x: a failed clinical trial that did not test the proposed mechanism of action. Clin Pharmacol Ther (in press).
69. Roses AD (1996). From genes to mechanisms to therapies: lessons to be learned from neurological disorders. [see comment]. Nat Med 2: 267-269.
70. Roses AD (1997). A model for susceptibility polymorphisms for complex diseases: apolipoprotein e and alzheimer disease. Neurogenetics 1: 3-11.
71. Roses AD (2004). Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 5: 645-656.
72. Roses AD (2007). Genome-wide screening for drug discovery and companion diagnostics. Expert Opin Drug Discov 2: 489-501.
73. Roses AD (2008c). Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov (in press).
74. Roses AD, Gilbert J, Xu PT, Sullivan P, Popko B, Burkhart DS et al (1998). Cis-acting human apoe tissue expression element is associated with human pattern of intraneuronal apoe in transgenic mice. Neurobiol Aging 19: S53-S58.
75. Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW (2007a). Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J 7: 10-28.
76. Roses AD, St Jean PL, Ehm MG (2007b). Use of whole-genome association scans in disease gene identification, drug discovery and development. Idrugs 10: 797-804.
77. Russman BS (2007). Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol 22: 946-951.
78. Saunders AM, Roses AD (1993). Apolipoprotein e4 allele frequency, ischemic cerebrovascular disease, and Alzheimer's disease. [see comment]. Stroke 24: 1416-1417.
79. Schellenberg GD, Bird TD, Wijsman EM, Orr HT, Anderson L, Nemens E et al (1992). Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 258: 668-671.
80. Schmechel DE, Goldgaber D, Burkhart DS, Gilbert JR, Gajdusek DC, Roses AD et al (1988). Cellular localization of messenger rna encoding amyloid-beta-protein in normal tissue and in alzheimer disease. Alzheimer Dis Assoc Disord 2: 96-111.
81. Schymick JC, Scholz SW, Fung HC, Britton A, Arepalli S, Gibbs JR et al (2007). Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. [see comment]. Lancet Neurol 6: 322-328.
82. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL et al (2007). A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316: 1341-1345.
83. Selkoe DJ, Wolfe MS (2007). Presenilin: running with scissors in the membrane. Cell 131: 215-221.
84. Serretti A, Kato M, Kennedy JL (2008). Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J 8: 90-100.
85. Sherrington R, Froelich S, Sorbi S, Campion D, Chi H, Rogaeva EA et al (1996). Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet 5: 985-988.
86. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D et al (2007). A genomewide association study identifies novel risk loci for type 2 diabetes. [see comment]. Nature 445: 881-885.
87. St George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins PC et al (1987). The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 235: 885-890.
88. Strittmatter WJ, Huang DY, Bhasin R, Roses AD, Goldgaber D (1993). Avid binding of beta an amyloid peptide to its own precursor. Exp Neurol 122: 327-334.
89. Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St George-Hyslop P, Van Keuren ML et al (1987). Amyloid beta protein gene: Cdna, mrna distribution, and genetic linkage near the Alzheimer locus. Science 235: 880-884.
90. Townsend M, Mehta T, Selkoe DJ (2007). Soluble abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 282: 33305-33312.
91. Walsh DM, Selkoe DJ (2007). A beta oligomers - a decade of discovery. J Neurochem 101: 1172-1184.
92. Warren LL, Hughes AR, Lai EH, Zaykin DV, Haneline SA, Bansal AT, et al, teams CNAaCs (2007). Use of pairwise marker combination and recursive partitioning in a pharmacogenetic genome-wide scan. Pharmacogenomics J 7: 180-189.
93. Wellcome Trust Case Control Consortium (2007). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. [see comment]. Nature 447: 661-678.
94. Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y et al (2006). Profile and regulation of apolipoprotein e (apoe) expression in the cns in mice with targeting of green fluorescent protein gene to the apoe locus. J Neurosci 26: 4985-4994.
95. Zaks TZ, Akkari A, Briley L, Mosteler M, Stead AG, Koch KM et al (2006). Role of pharmacogenetic studies in early clinical development: phase i studies with lapatinib. J Clin Oncol 24: 3029.
96. Zanke BW, Greenwood CM, Rangrej J, Kustra R, Tenesa A, Farrington SM et al (2007). Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 39: 989-994.
97. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H et al (2007). Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316: 1336-1341.
98. Ziedan NI, Kadri H, Westwell AD (2008). The development of pro-apoptotic cancer therapeutics. Mini Rev Med Chem 8: 711-718.